Only 30-50% of medicines available for children in Europe: MEP Cyrus Engerer

“We are in a situation where only 30-50% of medicines in Europe are available for children,” said MEP Cyrus Engerer.

This is a result of a lack of adequate investment in innovative research activities and a lack of infrastructure support, explains Engerer.

“In my work for the special committee on the fight against cancer, I focus a lot on unmet medical needs for treatments for childhood cancer, which remains the leading cause of death from disease in children over one year old in Europe,” he said.

The Special Committee on Cancer focuses on legislation to support research, prevention and equal access to treatment. The European Parliament voted in June 2020 to set up this special committee.

The Special Commission on the Fight Against Cancer was set up to look at ways in which the EU can take concrete action to tackle cancer and its effects on people’s lives. Her work includes identifying legislation and other measures that can help prevent and fight cancer, and exploring the best ways to support research.

Engerer is now calling for a number of concrete actions in this area. He suggested reducing delays in starting pediatric drug development and increasing incentives for the industry. Engerer also suggested allocating public investment in the development of medicines for children. “Children are our future and nothing should stand in their way of providing them with the best available treatments in an emergency,” he said.

More than a million people in the EU die each year from cancer – more than a quarter of all deaths – and millions of others have their lives turned upside down by the disease. In 2020, 2.7 million people in the European Union were diagnosed with cancer and another 1.3 million people died, including more than 2,000 young people. Cancer cases are expected to increase by 24% by 2035, making it the leading cause of death in the EU. Europe’s Beating Cancer Plan will have €4 billion in funding, including €1.25 billion from the future EU4Health programme.

This article is part of a content series called Ewropej. This is a multimedia in-house initiative partly funded by the European Parliament to bring the EP’s work closer to the citizens of Malta and keep them informed about matters that affect their daily lives. These articles reflect the opinions of the authors only.

The European Parliament is not responsible for any use made of the information contained in these articles.

Independent journalism costs money. Support Times of Malta for the price of a cup of coffee.

Support us

Comments are closed.